64 M
Prevalence of Heart Failure
284 B
Annual Economic Burden
50%
Mortality rate
1/4
Lifetime risk of heart failure
Transforming heart repair with safer, scalable, and life-changing regenerative solutions
VentriNaya aims to build scalable, off-the-shelf regenerative gene and cell therapy platforms to treat cardiovascular diseases—addressing the urgent need to prevent rehospitalization in patients with otherwise incurable heart conditions, and delivering long-term, single-dose solutions aligned with payer priorities.
Pipeline
Two Breakthrough approaches to regenerate injured hearts
VN-100: Cyclin A2 (CCNA2) Gene Therapy
Cyclin A2–treated porcine hearts exhibit marked cardiac regeneration after Myocardial Infarction using multimodality-imaging and cellular assays
VN-101: Placental CDX2+ Stem Cell Therapy
CDX2 cell delivery significantly improves cardiac function after acute Myocardial Infarction
Two Breakthrough approaches to regenerate injured hearts
Our Team
Executive leadership
Hina W. Chaudhry
M.D.
Co-founder
Sangeetha Vadakke-Madathil, Ph.D.
Co-founder
Board of Directors And Scientific Advisory Board
Coming soon
Company name
Coming soon
Company name
Coming soon
Company name